N1 Life

Executive Summary

N1 Life is a Stanford University spinout pioneering a peptide-based drug delivery platform that enhances solubility, penetration, and targeted efficacy of active ingredients. Founded in 2019 and based in Silicon Valley, the company initially focused on skincare applications but is expanding into therapeutic uses. Its proprietary technology, which utilizes peptide drug conjugates, addresses key challenges in drug delivery, particularly for topical and transdermal routes. By improving the bioavailability of existing and novel compounds, N1 Life aims to enable more effective treatments for dermatological and other conditions. The platform's versatility and the team's deep academic roots position the company as a promising early-stage player in the drug delivery space. To date, N1 Life has operated with limited public financing details, suggesting it is still in the preclinical or early clinical phase. The company's primary value driver is the validation of its platform through partnerships with cosmetic and pharmaceutical firms. Success in proving the platform's ability to deliver drugs more efficiently could unlock significant licensing and co-development opportunities. However, as a private company with no disclosed revenue or regulatory milestones, N1 Life faces typical early-stage risks including capital requirements and technical de-risking. Its conviction score reflects a promising but unproven platform.

Upcoming Catalysts (preview)

• Q3 2026First Major Licensing Deal with a Skincare or Pharma Company60% success
• Q4 2026Publication of Preclinical Efficacy Data in a Peer-Reviewed Journal80% success
• Q1 2027Closing of Series A Financing Round70% success